CompletedNCT04513912
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Medication studyAges 18–74Multiple countriesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 74 years.
- Listed locations
- Birmingham and 174 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 15, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 757
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT04513912
- Official title
Show the full official title
Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Get this study by email
Recruitment & locations
CompletedBirmingham, United States · Tucson, United States · Culver City, United States
137 more locations
- Encino, United States
- Garden Grove, United States
- Long Beach, United States
- Los Alamitos, United States
- Los Angeles, United States
- Newport Beach, United States
- Orange, United States
- Pico Rivera, United States
- Rancho Cucamonga, United States
- Redlands, United States
- San Diego, United States
- Santa Ana, United States
- Santee, United States
- Sherman Oaks, United States
- Upland, United States
- Hartford, United States
- Doral, United States
- Hallandale, United States
- Hialeah, United States
- Lakeland, United States
- Miami, United States
- Orlando, United States
- Tampa, United States
- The Villages, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Chicago, United States
- Libertyville, United States
- Lisle, United States
- Naperville, United States
- Oakbrook Terrace, United States
- Wichita, United States
- New Orleans, United States
- Baltimore, United States
- New Bedford, United States
- Roslindale, United States
- O'Fallon, United States
- Toms River, United States
- Brooklyn, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Durham, United States
- Cincinnati, United States
- Dayton, United States
- North Canton, United States
- Oklahoma City, United States
- Pine Hill, United States
- Scranton, United States
- Mt. Pleasant, United States
- Bellaire, United States
- Fort Worth, United States
- Mansfield, United States
- The Woodlands, United States
- Wichita Falls, United States
- Clinton, United States
- Draper, United States
- Charlottesville, United States
- Bellevue, United States
- Everett, United States
- Waukesha, United States
- Buenos Aires, Argentina
- Ciudad Autonoma Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- San Miguel de Tucumán, Argentina
- Bruges, Belgium
- Sint-Niklaas, Belgium
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Stara Zagora, Bulgaria
- Tzarev Brod, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Sydney, Canada
- Toronto, Canada
- Montreal, Canada
- Brno, Czechia
- Hradec Králové, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Jelgava, Latvia
- Liepāja, Latvia
- Outpatient Centre of Psychiatry, Latvia
- Riga, Latvia
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Ipoh, Malaysia
- Johor Bahru, Malaysia
- Pulau Pinang, Malaysia
- Seremban, Malaysia
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Lodz, Poland
- Lublin, Poland
- Poznan, Poland
- Warsaw, Poland
- Engel's, Russia
- Kemerovo, Russia
- Lipetsk Region, Russia
- Moscow, Russia
- Omsk, Russia
- Saint Petersburg, Russia
- Tomsk, Russia
- Yekaterinburg, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Banská Bystrica, Slovakia
- Bojnice, Slovakia
- Košice, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Trenčín, Slovakia
- Žilina, Slovakia
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Nove, Ukraine
- Ternopil, Ukraine
- Zaporizhzhya, Ukraine
- Derby, United Kingdom
- Greater Manchester, United Kingdom
- Harrogate, United Kingdom
- London, United Kingdom
- Redruth, United Kingdom
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Seltorexant, Matching placebo to Seltorexant, Quetiapine XR and Matching placebo to Quetiapine XR.
Who was this study for?
Listed age limits: 18 years to 74 years.
